The combination of SGLT2is and GLP-1 RAs in T2DM provides synergistic benefits for cardiovascular risk reduction, glycaemic control, weight, and blood pressure, without a significant increase in adverse events. This evidence concerns the gene GCG and type 2 diabetes mellitus.